EcoDrugPlus

60s Ribosomal Protein L8-Like

Ensembl ID : ENSCSEG00000006542
Gene Symbol: LOC103399068
3 Cross references
276 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCSEG00000016527
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCSEG00000006123
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCSEG00000011567
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCSEG00000021555
Gene Symbol: ADRM1
1 Cross references
193 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSCSEG00000000152
Gene Symbol: AKT1
3 Cross references
196 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSCSEG00000011899
Gene Symbol: ABCC1
3 Cross references
203 Possible Orthologues:

Atp-Binding Cassette Sub-Family C Member 8

Ensembl ID : ENSCSEG00000015332
Gene Symbol: LOC103398783
3 Cross references
228 Possible Orthologues:

Atp-Binding Cassette Sub-Family C Member 8-Like

Ensembl ID : ENSCSEG00000009012
Gene Symbol: LOC103380395
2 Cross references
172 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 9

Ensembl ID : ENSCSEG00000003388
Gene Symbol: ABCC9
1 Cross references
233 Possible Orthologues:

Atp-Sensitive Inward Rectifier Potassium Channel 11

Ensembl ID : ENSCSEG00000009004
Gene Symbol: LOC103380356
3 Cross references
189 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSCSEG00000001076
Gene Symbol: ATP1A1
4 Cross references
326 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).